A genetic trait hiding in plain sight
The trait is called hereditary alpha-tryptasemia, or HαT for short. It was only discovered in 2015.
People with HαT carry extra copies of a gene called TPSAB1. This gene tells the body to make a protein called alpha-tryptase.
Here’s the catch. About 4 to 6 percent of people with European ancestry carry this trait. That means millions of people may have it and not know.
Roughly one in three people who test positive develop real symptoms. These can include skin flushing, allergic reactions, and stubborn stomach issues.
Why the gut keeps suffering
Celiac disease affects about 1 in 100 people worldwide. Inflammatory bowel disease (IBD), which includes Crohn’s and ulcerative colitis, affects millions more.
The standard advice for celiac is clear. Cut out gluten, and the gut should heal.
But many patients stay sick. They follow the diet, their blood tests improve, and yet the pain, bloating, and urgent bathroom trips continue.
For IBD patients, the story is similar. Treatments have improved, but many people still flare up without warning. Doctors have long blamed overactive T-cells, a type of immune soldier.
That picture may have been incomplete.
The old story versus the new
For decades, scientists focused on T-cells as the main villain in gut inflammation. They designed drugs to calm those cells down.
But here’s the twist. A different immune cell, called a mast cell, may be playing a much bigger role than anyone realized.
Mast cells are like alarm systems in your tissues. When they sense trouble, they release chemicals that cause swelling, pain, and cramping.
One of those chemicals is tryptase, the same protein pumped out in extra amounts by people with HαT.
Think of it like a stuck alarm
Imagine your gut as a quiet neighborhood. Mast cells are the home security systems in each house.
In healthy people, these alarms only go off when real danger shows up. They sound briefly, then reset.
In people with HαT, the alarms are wired to be louder and touchier. Small bumps that would normally be ignored can trigger a full-scale response.
That means more inflammation, more pain, and more signals telling the body something is wrong, even when the main threat is gone.
This overactive alarm may be why some patients never fully feel better, even on the “right” treatment.
Researchers reviewed emerging studies on HαT and the gut. They looked at people with celiac disease, IBD, and those with no obvious gut disease at all.
The findings were striking. Even people without a diagnosed gut disease showed changes in the small intestine if they carried HαT.
In celiac patients with HαT, doctors found more mast cells packed into the duodenum, the top part of the small intestine. These patients were more likely to still have diarrhea, bloating, and abdominal pain despite a strict gluten-free diet.
In IBD, extra copies of the alpha-tryptase gene were linked to more mast cell activation. Scientists also saw higher levels of a receptor called MRGPRX2, which acts like a new trigger button on mast cells.
This is where things get interesting
The picture forming now is that HαT doesn’t cause one single disease. Instead, it quietly changes how many different gut conditions behave.
It’s like turning up the volume on a radio. The song is the same, but everything feels louder and more intense.
Where experts see this heading
Specialists in allergy and gastroenterology have been watching HαT closely since its discovery. Many now view it as a “disease modifier,” not a disease in itself.
That shift in thinking matters. It means doctors may need to test for HαT in patients whose gut symptoms don’t match their test results or don’t improve with standard care.
It also opens the door to new treatments that target mast cells directly, rather than only focusing on T-cells.
If you have celiac disease, IBD, or unexplained gut symptoms that don’t get better with treatment, HαT may be worth discussing with your doctor.
A simple blood test can measure baseline tryptase levels. Genetic testing can confirm the trait.
Knowing you carry HαT won’t cure your symptoms. But it can help your care team understand why you might need a different approach.
The limits of what we know
This is still early research. Much of the evidence comes from small studies and reviews, not large clinical trials.
Scientists also don’t yet fully understand why only one-third of people with HαT develop symptoms. The gene dosage matters, but other factors likely play a role too.
Researchers are now exploring medicines that block mast cell activity or target the MRGPRX2 receptor. Some of these drugs are already being tested for other allergic conditions.
Larger studies are needed to see if treating HαT directly can ease gut symptoms in celiac and IBD patients. That work is underway, but approvals for gut-specific use could take years.
For now, the biggest shift is awareness. Doctors who know to look for HαT can give patients something they’ve often lacked: a real explanation for symptoms that never seemed to add up.
